Eisai files application in Japan for Alzheimer's drug lecanemab
travellinglight/iStock via Getty Images                 

Eisai (OTCPK:ESALY)(OTCPK:ESALF) has submitted a marketing authorization application to regulators in Japan for the Alzheimer's disease treatment lecanemab.
The application is supported by results from the phase III Clarity AD study and a phase IIb study, both of which showed lecanemab led to a reduction in clinical decline in early Alzheimer's.
The Japanese drugmaker just filed a lecanemab application with the European Medicines Agency on Jan. 11.
With US partner Biogen (BIIB), the treatment, known as Leqembi, was approved by the US FDA earlier in January.